In neoadjuvant settings, ctDNA monitoring allows for real-time therapy adjustment. Data from the iSpy platform shows 80% of hormone-positive patients clear ctDNA with half the chemotherapy, enabling de-escalation, while the remaining 20% can be identified for escalated treatment.

The extreme effectiveness of frontline BEP chemotherapy makes it nearly impossible to replace. This forces novel drug development into the small, refractory patient population. This niche market makes it economically challenging for pharmaceutical companies to invest in large-scale trials, thus slowing innovation for new agents.

After years of successfully intensifying hormonal therapy, the focus in prostate cancer is shifting toward de-intensification. Researchers are exploring intermittent therapy for top responders and developing non-hormonal approaches like radioligands to spare patients the chronic, life-altering side effects of permanent castration.

A subset of breast cancers (10-15%) are "non-shedders," meaning they don't release detectable ctDNA. Patients with these tumors have excellent outcomes regardless of chemotherapy, suggesting that surgery alone might be a sufficient and less toxic treatment for this specific group.

In the refractory setting for testis cancer, there is no established standard of care. This makes conducting large, randomized trials ethically and practically difficult. Therefore, well-conducted single-arm trials showing modest but meaningful activity, such as with cabozantinib, can still provide reasonable options for patients with no alternatives.

The next wave of ctDNA research focuses on de-escalation. Trials like SIGNAL ER101 and an Alliance cooperative group study will test withholding intensive adjuvant treatments (like CDK4/6 inhibitors) in high-risk, ctDNA-negative patients, initiating therapy only if they turn positive later. This could spare many from toxicity and cost.

The next major advance in adjuvant kidney cancer will be a biomarker to select who needs treatment. The key is developing a Minimal Residual Disease (MRD) test based on the epigenome (e.g., chromatin modifications) rather than just ctDNA mutations. This is because the critical biological signals in RCC are found in epigenetic regulation, not just the genome.

Experts advise against using gene expression profiling to escalate care for CSCC (e.g., deciding to add systemic therapy). Its primary utility is in de-escalation: a low-risk profile can provide an additional data point to support a decision for observation in a borderline high-risk case, helping to avoid overtreatment.

Germ cell tumors are extremely sensitive to chemotherapy due to intrinsic biological factors, not the immune environment. Their DNA is relatively hypomethylated, leaving it more open to damage, and they have intact apoptosis mechanisms with low rates of P53 mutation. This explains why they respond so well to chemo but poorly to traditional checkpoint inhibitors.